The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of a stop light tool using the bellarmine norton assessment tool (BNAT) for physical therapy referral.
 
Catherine Elizabeth Crandell
No Relationships to Disclose
 
Christopher Jon Wingard
No Relationships to Disclose
 
Sarah Elizabeth Quinn
No Relationships to Disclose
 
Kate Elise Amin
No Relationships to Disclose
 
Katie Marie Brownschidle
No Relationships to Disclose
 
Donna Dahm
No Relationships to Disclose
 
Lauren Huebler
No Relationships to Disclose
 
Kelsey Lynn Mayo
No Relationships to Disclose
 
John Turner Hamm
Honoraria - BrightPath Biotheraputics; Exelixis; Puma Biotechnology
Consulting or Advisory Role - Meda Pharmaceuticals; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); BrightPath Biotheraputics (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dana-Farber Cancer Institute (Inst); Deciphera (Inst); EMD Serono (Inst); EpicentRx (Inst); Exact Sciences (Inst); Five Prime Therapeutics (Inst); G1 Therapeutics (Inst); GBG Forschungs (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Halozyme (Inst); Immunicum (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Moffitt (Inst); National Surgical Adjuvant Breast and Bowel Project (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Pronova (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); SWOG (Inst)